Table 2.
Inflammatory bowel disease-specific medication use in the six months prior to initial stage of surgery
| Patients without pouchitis n=287 | Patients with pouchitis n=260 | p-value | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Mesalamine | 107 | 37 | 141 | 54 | <0.001 |
| Sulfasalazine | 11 | 4 | 9 | 3 | 0.817 |
| Balsalazide | 27 | 9 | 25 | 10 | 0.934 |
| Immunomodulator (azathiopurine, mercaptopurine, or methotrexate) | 58 | 20 | 66 | 25 | 0.149 |
| Tacrolimus | 4 | 1 | 3 | 1 | 0.803 |
| Cyclosporine | 2 | 1 | 1 | 0 | 0.664 |
| Anti-TNF therapy | 68 | 24 | 92 | 35 | 0.003 |
| Prednisone | 133 | 46 | 144 | 55 | 0.035 |
| Budesonide (MMX and enteral release) | 13 | 5 | 21 | 8 | 0.086 |
Anti-tumor necrosis factor alpha (anti-TNF); multimatrix (MMX)